Pharmacology · Cardiovascular

Proarrhythmia, Drug Interactions, and Special Populations

QT prolongation and torsades de pointes, key drug interactions, renal dosing, and special populations

Drug-induced torsades de pointes is pause-dependent and affects women 70% of the time; the highest-risk conditions are corrected QT interval exceeding 500 ms, hypokalemia, hypomagnesemia, bradycardia, and combinations of QT-prolonging drugs — the treatment sequence is drug withdrawal, IV magnesium, electrolyte correction targeting K⁺ ≥ 4.5 mEq/L, then heart rate increase with isoproterenol or temporary pacing.
Amiodarone drives the most clinically significant antiarrhythmic drug interactions: it raises the INR 30–50% with warfarin (reduce warfarin by one-third), doubles digoxin levels (halve the digoxin dose), raises flecainide levels (reduce flecainide by 50%), and causes myopathy risk with simvastatin and lovastatin (switch to pravastatin or rosuvastatin); these effects persist weeks after amiodarone is stopped due to its long half-life.
Verapamil, cimetidine, and trimethoprim are absolutely contraindicated with dofetilide — all three reduce renal cation transport, sharply raising dofetilide levels and causing dangerous QT prolongation.
Renal impairment requires formal dose adjustment for sotalol (contraindicated below CrCl 40), dofetilide (four-tier adjustment, contraindicated below CrCl 20), digoxin, procainamide, and flecainide; amiodarone, lidocaine, and mexiletine are primarily hepatically cleared and are the safest antiarrhythmics in severe chronic kidney disease.
In pregnancy, adenosine is first-line for acute SVT, beta-blockers and digoxin are relatively safe, and direct-current cardioversion is safe at any gestational age; amiodarone should be avoided — its iodine content causes neonatal hypothyroidism — and reserved only for life-threatening refractory arrhythmia; in elderly patients, start at half the standard dose, formally calculate renal function, and review all co-medications for cumulative QT-prolonging burden.

Drug-Induced QT Prolongation and Torsades de Pointes

Risk Factors — Amplify Torsades de Pointes Risk

When QT Prolongation Becomes Dangerous

Female sex (70% of drug-induced torsades de pointes)
Hypokalemia and hypomagnesemia — correct before and during therapy
Bradycardia and pauses — torsades de pointes is pause-dependent
Corrected QT interval over 500 ms — stop or reduce the offending drug
Multiple QT-prolonging drugs — avoid combinations (Class Ia + Class III, antiarrhythmics + fluoroquinolones, azoles, antipsychotics)
Structural heart disease, left ventricular hypertrophy

Acute Management

Torsades de Pointes Protocol

Step 1: Withdraw offending drug immediately
Step 2: Intravenous magnesium sulfate — first-line regardless of serum level
Step 3: Correct electrolytes — target K+ at or above 4.5 mEq/L
Step 4: Increase heart rate — isoproterenol infusion or temporary pacing at 90 to 110 beats per minute
Step 5: Defibrillate if degenerates to ventricular fibrillation
Do NOT give calcium in acquired torsades de pointes

Key Antiarrhythmic Drug Interactions

Combination	Clinical Consequence	Management
Amiodarone + warfarin	International normalized ratio rises 30 to 50%; bleeding risk	Reduce warfarin dose by one-third; monitor weekly x 4 to 8 weeks; persists after amiodarone stopped
Amiodarone + digoxin	Digoxin levels double; toxicity risk	Halve digoxin dose; recheck levels within 1 to 2 weeks
Amiodarone + simvastatin or lovastatin	Statin levels rise; myopathy and rhabdomyolysis risk	Avoid simvastatin above 20 mg; prefer pravastatin or rosuvastatin
Amiodarone + flecainide	Flecainide levels rise; QRS widening; ventricular tachycardia risk	Reduce flecainide dose by 50%; monitor electrocardiogram
Sotalol + diuretics	Hypokalemia amplifies QT prolongation; torsades de pointes risk	Maintain K+ at or above 4.5 mEq/L; monitor electrolytes regularly
Dofetilide + verapamil, cimetidine, or trimethoprim	Dofetilide levels rise sharply; dangerous QT prolongation	All three are absolutely contraindicated with dofetilide

Renal Impairment and Special Populations

Renal Impairment

Dose Adjustment Required

Sotalol: 100% renally eliminated; contraindicated if creatinine clearance below 40 mL/min
Dofetilide: 80% renally eliminated; four-tier dose adjustment; contraindicated if creatinine clearance below 20 mL/min
Digoxin: 70 to 80% renally eliminated; narrow therapeutic index; reduce proportionally
Procainamide: renally eliminated; reduce dose and frequency in renal impairment
Flecainide: 30% renal; reduce when creatinine clearance below 35 mL/min

Renal Impairment

Safe Without Renal Adjustment

Amiodarone: primarily hepatic clearance; safest antiarrhythmic in severe chronic kidney disease
Lidocaine: primarily hepatic; no intravenous renal dose adjustment
Mexiletine: approximately 90% hepatic; minor consideration in severe chronic kidney disease only

Pregnancy

Safe vs. Avoid

Adenosine — safest; first-line acute supraventricular tachycardia; negligible fetal exposure
Beta-blockers — relatively safe; metoprolol preferred over atenolol
Digoxin — relatively safe; also treats fetal supraventricular tachycardia via placenta
Direct-current cardioversion — safe at any gestational age
Amiodarone — AVOID; neonatal hypothyroidism (iodine), intrauterine growth restriction; use only for life-threatening refractory arrhythmia

Elderly Patients

Key Prescribing Rules

Start at half the standard adult dose; uptitrate cautiously
Calculate renal function formally — serum creatinine alone underestimates impairment
Corrected QT interval monitoring mandatory at initiation and after dose changes
Digoxin target: 0.5 to 0.8 nanograms per milliliter (lower than historical targets)
Review all co-medications for QT-prolonging agents (polypharmacy risk)
Annual amiodarone monitoring more critical in elderly than younger patients

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Roden DM	Drug-induced prolongation of the QT interval	N Engl J Med. 2004;350(10):1013–1022
Woosley RL, Heise CW, Gallo T, Woosley D, Romero KA	CredibleMeds Combined Risk QTDrugs List	AZCERT, Inc. Available at: www.CredibleMeds.org
Tisdale JE, Jayes HA, Kingery JR, et al	Development and validation of a risk score to predict QT-interval prolongation in hospitalized patients	Circ Cardiovasc Qual Outcomes. 2013;6(4):479–487
Matzke GR, Aronoff GR, Atkinson AJ Jr, et al	Drug dosing consideration in patients with acute and chronic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)	Kidney Int. 2011;80(11):1122–1137
Page RL, Joglar JA, Caldwell MA, et al	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia	J Am Coll Cardiol. 2016;67(13):e27–e115
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al	2018 ESC guidelines for the management of cardiovascular diseases during pregnancy	Eur Heart J. 2018;39(34):3165–3241
Joglar JA, Chung MK, Armbruster AL, et al	2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation	J Am Coll Cardiol. 2024;83(1):109–279
Fleg JL, Strait J	Age-associated changes in cardiovascular structure and function: a fertile milieu for future disease	Heart Fail Rev. 2012;17(4-5):545–554
Goldberger JJ, Cain ME, Hohnloser SH, et al	American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death	Circulation. 2008;118(14):1497–1518